Emily Bodnar
Stock Analyst at HC Wainwright & Co.
(3.34)
# 977
Out of 5,162 analysts
336
Total ratings
26.92%
Success rate
9.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SABS SAB Biotherapeutics | Maintains: Buy | $9 → $7 | $4.29 | +63.17% | 3 | Mar 10, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $36 → $38 | $14.45 | +162.98% | 24 | Mar 9, 2026 | |
| SANA Sana Biotechnology | Maintains: Buy | $9 → $7 | $3.32 | +110.84% | 13 | Mar 4, 2026 | |
| ANAB AnaptysBio | Maintains: Buy | $51 → $66 | $63.51 | +3.92% | 14 | Mar 4, 2026 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $32 | $22.06 | +45.06% | 8 | Mar 2, 2026 | |
| NVCR NovoCure | Maintains: Buy | $47 → $49 | $12.04 | +306.98% | 22 | Feb 26, 2026 | |
| ACLX Arcellx | Downgrades: Neutral | $115 | $114.40 | +0.53% | 15 | Feb 23, 2026 | |
| AUTL Autolus Therapeutics | Initiates: Buy | $9 | $1.45 | +520.69% | 1 | Feb 17, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $62 → $65 | $27.47 | +136.62% | 5 | Feb 12, 2026 | |
| VTVT vTv Therapeutics | Maintains: Buy | $36 → $47 | $32.19 | +46.01% | 3 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $1.61 | +1,080.12% | 13 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $15 | $6.12 | +145.10% | 2 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $5 | $3.15 | +58.73% | 13 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.94 | +1,172.94% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $60 | $27.51 | +118.10% | 1 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.22 | - | 14 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.10 | +641.94% | 20 | Sep 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $4.33 | +823.79% | 15 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $35 | $9.90 | +253.54% | 14 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $0.55 | +1,342.74% | 25 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $20 | $1.24 | +1,514.21% | 10 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $13.26 | +171.49% | 9 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $560 → $280 | $9.55 | +2,831.94% | 17 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.86 | +179.72% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $2.54 | +1,081.10% | 7 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $2.26 | +696.46% | 15 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $183 | $3.00 | +5,987.00% | 12 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $35 | $5.20 | +573.08% | 14 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.58 | - | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $330 | $3.89 | +8,383.29% | 14 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $2.45 | - | 1 | Apr 25, 2024 |
SAB Biotherapeutics
Mar 10, 2026
Maintains: Buy
Price Target: $9 → $7
Current: $4.29
Upside: +63.17%
Olema Pharmaceuticals
Mar 9, 2026
Maintains: Buy
Price Target: $36 → $38
Current: $14.45
Upside: +162.98%
Sana Biotechnology
Mar 4, 2026
Maintains: Buy
Price Target: $9 → $7
Current: $3.32
Upside: +110.84%
AnaptysBio
Mar 4, 2026
Maintains: Buy
Price Target: $51 → $66
Current: $63.51
Upside: +3.92%
Arcus Biosciences
Mar 2, 2026
Reiterates: Buy
Price Target: $32
Current: $22.06
Upside: +45.06%
NovoCure
Feb 26, 2026
Maintains: Buy
Price Target: $47 → $49
Current: $12.04
Upside: +306.98%
Arcellx
Feb 23, 2026
Downgrades: Neutral
Price Target: $115
Current: $114.40
Upside: +0.53%
Autolus Therapeutics
Feb 17, 2026
Initiates: Buy
Price Target: $9
Current: $1.45
Upside: +520.69%
Agios Pharmaceuticals
Feb 12, 2026
Maintains: Buy
Price Target: $62 → $65
Current: $27.47
Upside: +136.62%
vTv Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $36 → $47
Current: $32.19
Upside: +46.01%
Nov 25, 2025
Reiterates: Buy
Price Target: $19
Current: $1.61
Upside: +1,080.12%
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $15
Current: $6.12
Upside: +145.10%
Nov 6, 2025
Maintains: Buy
Price Target: $4 → $5
Current: $3.15
Upside: +58.73%
Oct 14, 2025
Initiates: Buy
Price Target: $12
Current: $0.94
Upside: +1,172.94%
Oct 6, 2025
Assumes: Buy
Price Target: $60
Current: $27.51
Upside: +118.10%
Sep 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.22
Upside: -
Sep 10, 2025
Reiterates: Buy
Price Target: $23
Current: $3.10
Upside: +641.94%
Aug 27, 2025
Maintains: Buy
Price Target: $32 → $40
Current: $4.33
Upside: +823.79%
Aug 15, 2025
Upgrades: Buy
Price Target: $35
Current: $9.90
Upside: +253.54%
Aug 11, 2025
Maintains: Buy
Price Target: $12 → $8
Current: $0.55
Upside: +1,342.74%
Jul 7, 2025
Maintains: Buy
Price Target: $40 → $20
Current: $1.24
Upside: +1,514.21%
Jul 1, 2025
Reiterates: Buy
Price Target: $36
Current: $13.26
Upside: +171.49%
Apr 16, 2025
Maintains: Buy
Price Target: $560 → $280
Current: $9.55
Upside: +2,831.94%
Apr 1, 2025
Reiterates: Buy
Price Target: $8
Current: $2.86
Upside: +179.72%
Mar 31, 2025
Reiterates: Buy
Price Target: $30
Current: $2.54
Upside: +1,081.10%
Mar 27, 2025
Reiterates: Buy
Price Target: $18
Current: $2.26
Upside: +696.46%
Mar 26, 2025
Reiterates: Buy
Price Target: $183
Current: $3.00
Upside: +5,987.00%
Mar 26, 2025
Reiterates: Buy
Price Target: $35
Current: $5.20
Upside: +573.08%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.58
Upside: -
Nov 15, 2024
Reiterates: Buy
Price Target: $330
Current: $3.89
Upside: +8,383.29%
Apr 25, 2024
Reiterates: Neutral
Price Target: n/a
Current: $2.45
Upside: -